Literature DB >> 20622991

Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells.

Zhanglin Ni1, Michelle E Mark, Xiaokun Cai, Qingcheng Mao.   

Abstract

The human breast cancer resistance protein (BCRP/ABCG2) is a half ATP-binding cassette (ABC) efflux transporter that plays an important role in drug resistance and disposition. Although BCRP is believed to function as a homodimer or homooligomer, this has not been demonstrated in vivo in intact cells. Therefore, in the present study, we investigated dimer/oligmer formation of BCRP in intact cells. Wild-type BCRP and the mutant C603A were attached to cyan or yellow fluorescence protein and expressed in HEK293 cells by transient transfection. Protein levels, cell surface expression, and efflux activities of wild-type and mutant BCRP were determined by immunoblotting, 5D3 antibody binding, and flow cytometric efflux assay, respectively. Dimer/oligomer formation of BCRP in intact cells was analyzed using fluorescence resonance energy transfer (FRET) microscopy. Wild-type BCRP and C603A were expressed in HEK293 cells at comparable levels. C603A was predominantly expressed in the plasma membrane as was wild-type protein. Furthermore, C603A retained the same mitoxantrone efflux activity and the ability of dimer/oligmer formation as wild-type BCRP. Finally, cross-linking experiments yielded data consistent with the FRET analysis. In conclusion, we have, for the first time, demonstrated that BCRP can form a dimer/oligomer in vivo in intact cells using the FRET technique. We have also shown that Cys(603) alone does not seem to be essential for dimer/oligomer formation of BCRP.

Entities:  

Year:  2010        PMID: 20622991      PMCID: PMC2901148     

Source DB:  PubMed          Journal:  Int J Biochem Mol Biol        ISSN: 2152-4114


  40 in total

1.  Fluorescence resonance energy transfer from cyan to yellow fluorescent protein detected by acceptor photobleaching using confocal microscopy and a single laser.

Authors:  T S Karpova; C T Baumann; L He; X Wu; A Grammer; P Lipsky; G L Hager; J G McNally
Journal:  J Microsc       Date:  2003-01       Impact factor: 1.758

2.  Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2.

Authors:  Ulla Henriksen; Jacob U Fog; Thomas Litman; Ulrik Gether
Journal:  J Biol Chem       Date:  2005-08-17       Impact factor: 5.157

Review 3.  ATP-binding cassette, subfamily G (ABCG family).

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pflugers Arch       Date:  2006-09-16       Impact factor: 3.657

4.  Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization.

Authors:  Kumie Kage; Satomi Tsukahara; Tomomi Sugiyama; Sakiyo Asada; Etsuko Ishikawa; Takashi Tsuruo; Yoshikazu Sugimoto
Journal:  Int J Cancer       Date:  2002-02-10       Impact factor: 7.396

5.  Role of the breast cancer resistance protein (ABCG2) in drug transport.

Authors:  Qingcheng Mao; Jashvant D Unadkat
Journal:  AAPS J       Date:  2005-05-11       Impact factor: 4.009

6.  FRET analysis indicates that the two ATPase active sites of the P-glycoprotein multidrug transporter are closely associated.

Authors:  Q Qu; F J Sharom
Journal:  Biochemistry       Date:  2001-02-06       Impact factor: 3.162

Review 7.  ABCG2: a perspective.

Authors:  Robert W Robey; Kenneth K K To; Orsolya Polgar; Marius Dohse; Patricia Fetsch; Michael Dean; Susan E Bates
Journal:  Adv Drug Deliv Rev       Date:  2008-12-16       Impact factor: 15.470

8.  Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2.

Authors:  Yang Liu; Youyun Yang; Jing Qi; Hui Peng; Jian-Ting Zhang
Journal:  J Pharmacol Exp Ther       Date:  2008-04-22       Impact factor: 4.030

9.  Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.

Authors:  Salvatore Cisternino; Claire Mercier; Fanchon Bourasset; Françoise Roux; Jean-Michel Scherrmann
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

10.  Live cell FRET microscopy: homo- and heterodimerization of two human peroxisomal ABC transporters, the adrenoleukodystrophy protein (ALDP, ABCD1) and PMP70 (ABCD3).

Authors:  Merle Hillebrand; Sophie E Verrier; Andreas Ohlenbusch; Annika Schäfer; Hans-Dieter Söling; Fred S Wouters; Jutta Gärtner
Journal:  J Biol Chem       Date:  2007-07-03       Impact factor: 5.157

View more
  18 in total

Review 1.  Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.

Authors:  Dustin R Walsh; Thomas D Nolin; Peter A Friedman
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 2.  Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions.

Authors:  Rebecca R Crawford; Praveen K Potukuchi; Erin G Schuetz; John D Schuetz
Journal:  Drug Metab Dispos       Date:  2018-03-07       Impact factor: 3.922

Review 3.  Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).

Authors:  Zhanglin Ni; Zsolt Bikadi; Mark F Rosenberg; Qingcheng Mao
Journal:  Curr Drug Metab       Date:  2010-09       Impact factor: 3.731

Review 4.  Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.

Authors:  Qingcheng Mao; Jashvant D Unadkat
Journal:  AAPS J       Date:  2014-09-19       Impact factor: 4.009

5.  Human ABCG2: structure, function, and its role in multidrug resistance.

Authors:  Wei Mo; Jian-Ting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2011-03-30

6.  Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity.

Authors:  Zhanglin Ni; Zsolt Bikadi; Diana L Shuster; Chunsheng Zhao; Mark F Rosenberg; Qingcheng Mao
Journal:  Biochemistry       Date:  2011-08-26       Impact factor: 3.162

7.  Different roles of TM5, TM6, and ECL3 in the oligomerization and function of human ABCG2.

Authors:  Wei Mo; Jing Qi; Jian-Ting Zhang
Journal:  Biochemistry       Date:  2012-04-19       Impact factor: 3.162

8.  Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules.

Authors:  Owen M Woodward; Deepali N Tukaye; Jinming Cui; Patrick Greenwell; Leeza M Constantoulakis; Benjamin S Parker; Anjana Rao; Michael Köttgen; Peter C Maloney; William B Guggino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

9.  Single-nucleotide polymorphisms in a short basic motif in the ABC transporter ABCG2 disable its trafficking out of endoplasmic reticulum and reduce cell resistance to anticancer drugs.

Authors:  Wenji Zhang; Yang Yang; Zizheng Dong; Zhi Shi; Jian-Ting Zhang
Journal:  J Biol Chem       Date:  2019-11-12       Impact factor: 5.157

10.  Cryptotanshinone Inhibits ERα-Dependent and -Independent BCRP Oligomer Formation to Reverse Multidrug Resistance in Breast Cancer.

Authors:  Wenting Ni; Hui Fan; Xiuqin Zheng; Fangming Xu; Yuanyuan Wu; Xiaoman Li; Aiyun Wang; Shile Huang; Wenxing Chen; Shijun Wang; Yin Lu
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.